Compare CIG & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIG | KRYS |
|---|---|---|
| Founded | 1952 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 7.8B |
| IPO Year | N/A | 2017 |
| Metric | CIG | KRYS |
|---|---|---|
| Price | $2.19 | $264.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $297.60 |
| AVG Volume (30 Days) | ★ 5.1M | 265.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 6.84 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $0.38 | $44.50 |
| Revenue Next Year | N/A | $34.79 |
| P/E Ratio | ★ $9.38 | $38.34 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $1.59 | $123.03 |
| 52 Week High | $2.41 | $298.30 |
| Indicator | CIG | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 46.66 |
| Support Level | $1.92 | $255.65 |
| Resistance Level | $2.28 | $293.60 |
| Average True Range (ATR) | 0.06 | 12.27 |
| MACD | -0.01 | -1.72 |
| Stochastic Oscillator | 22.41 | 25.98 |
Cia Energetica DE Minas Gerais - Cemig, formerly Energy Company of Minas Gerais, is a Brazilian power company that generates, transmits, and distributes electricity. As one of the power companies in Brazil, the firm operates across Brazilian states and Chile. The company has various subsidiaries and operates chiefly through its generation, transmission, distribution, and gas segments. The majority of the company's revenue is derived from electricity sales to consumers. The company generates power through hydroelectric resources and, secondarily, through thermal and wind resources.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.